Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark

The FDA has approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin indicated alongside diet and exercise to control high blood sugar in adults with type 2 diabetes.¹ It is designed to deliver steady basal insulin over seven days, which cuts annual injections from about 365 with a once-daily basal insulin to 52.

The US decision follows approvals by the EMA, Mexico's Federal Commission for the Protection against Sanitary Risks, and Japan's Pharmaceuticals and Medical Devices Agency.¹ It also makes efsitora the second once-weekly basal insulin available to US prescribers. Novo Nordisk expanded its metabolic portfolio when the FDA approved its once-weekly insulin icodec (Awiqli) for type 2 diabetes on the strength of ONWARDS phase III data.

"For over a century, Lilly has been developing insulins that transformed diabetes care for millions of people worldwide, but delays in initiating treatment and the burden of daily injections can have a real impact on patients' day-to-day experience managing type 2 diabetes," said Kenneth Custer, PhD, executive vice president and president, Lilly Cardiometabolic Health, in a press release.¹ "Onswik offers a new once-weekly basal insulin option for patients and reflects our continued commitment to deliver innovative treatment options that expand choice and provide greater flexibility in how people manage type 2 diabetes."

What Did the QWINT Trials Show?

The approval is based on the phase III QWINT program.¹ It enrolled more than 3,400 adults with type 2 diabetes across four studies covering three groups: patients new to insulin, patients switching from daily basal insulin, and patients who also use mealtime insulin. In each trial, efsitora met the primary endpoint of noninferior A1C reduction compared with once-daily insulin glargine or insulin degludec. QWINT-1 also tested a simplified fixed-dose escalation of 100, 150, 250, and 400 units, which could make it easier to start insulin.

Safety was similar to the daily comparators.¹ Efsitora is not indicated for type 1 diabetes because of an increased risk of severe hypoglycemia. Common side effects include hypoglycemia, allergic and injection-site reactions, lipodystrophy, rash, swelling of the hands and feet, and weight gain.

What Is the Impact of this Approval?

Efsitora's weekly profile comes from its molecular design.¹ It is a fusion protein that joins a novel single-chain insulin variant to the Fc domain of a human immunoglobulin G2 antibody, and this structure gives it a half-life of roughly 15 to 16 days. That Fc-fusion architecture puts efsitora closer to engineered biologics than to conventional recombinant insulin analogs, which affects expression, purification, and analytical control strategies. Icodec takes a different approach: it binds to albumin, forming an inactive depot that releases drug slowly over the week.

The drug product also raises formulation and device considerations.¹ The KwikPen will come in 500 units/mL and 1,000 units/mL concentrations, delivering up to 400 and 800 units per injection, respectively. That is far above the 100 units/mL comparators used in QWINT. The labeling emphasizes preventing dosing errors. It warns patients not to dial the maximum dose unless prescribed, not to withdraw product with a syringe, and to check labels to avoid mix-ups. When one injection carries a week of drug, human factors engineering and labeling become central to combination-product risk management.

The launch also draws on a manufacturing network Lilly has expanded over many years. The company's plans to expand insulin active-ingredient, delivery-device, and cartridge capacity across Indianapolis, Puerto Rico, France, and China.

How Is Lilly Reshaping Its Domestic Manufacturing Capabilities?

Efsitora's approval lands days after Lilly broke ground on a $6.5 billion API facility in Houston, its fifth domestic ingredient site among ten US manufacturing locations announced since 2020.² The plant will produce orforglipron (Foundayo), an oral glucagon-like peptide-1 receptor agonist. Because it is a small molecule rather than a peptide, it relies on more established and readily scalable technologies. The site will also make oligonucleotides and other advanced therapeutics, with machine learning, AI, and digitally integrated systems embedded to support right-first-time execution.

References

1. Eli Lilly and Company. U.S. Food and Drug Administration (FDA) approves Lilly’s Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment. Published September 24, 2026. Accessed September 24, 2026. https://investor.lilly.com/news-releases/news-release-details/us-food-and-drug-administration-fda-approves-lillys-onswiktm
2. Eli Lilly and Company. Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020. Published September 21, 2026. Accessed September 24, 2026. https://investor.lilly.com/news-releases/news-release-details/lilly-breaks-ground-houston-one-ten-us-manufacturing-sites